Rimmer Sophie, Dobson Marianne
Dental Core Trainee, Dundee Dental Hospital & Research School, Dundee, UK.
Specialty Registrar in Oral Medicine, Dundee Dental Hospital & Research School, Dundee, UK.
Evid Based Dent. 2025 Mar;26(1):48-49. doi: 10.1038/s41432-024-01096-2. Epub 2025 Mar 5.
This single-centre, short-term randomized control trial (RCT) assesses the effect of systemic amoxicillin and metronidazole as an adjunct to SRP in patients with severe periodontitis and type 2 diabetes mellitus (T2DM) on glycaemic control, over a 3-month period. The authors hypothesize that adjunctive systemic antibiotics will decrease systemic inflammation and subsequently improve glucose control. Baseline periodontal examinations and haematological tests were performed for all subjects. Subsequently, subgingival scaling and root planning (SRP) procedures were performed by a single periodontist for both the test and control groups. The test group received 500 mg amoxicillin and 200 mg metronidazole TDS for 7 days in the same week of the SRP procedure. Three months later, periodontal examinations were repeated by blinded examiners and haematological tests were repeated. Maintenance periodontal therapy was provided at this time.
A convenience sample of patients visiting the periodontal department between 2016-2022 was used. Participants included were aged 40-75; diagnosed with T2DM for >2 years; HbA1c of 6.5-10%, had stable medication regimens and >15 remaining teeth. Participants had a periodontal diagnosis of generalized severe chronic periodontitis or stage III-IV generalized periodontitis based on the 1999 and 2018 classifications respectively. Exclusion criteria related to coexisting inflammatory or infectious diseases (e.g. malignancy, coronary heart disease or hepatitis); adjustment in diet or glycaemic control strategy; severe diabetic complications; pregnancy or lactation; allergies to amoxicillin or metronidazole; periodontal treatment or antibiotics within 3 months prior; smoking and alcohol abuse. The primary clinical outcome was a change in HbA1c. Secondary outcomes included the effect on periodontal parameters and haematological markers of inflammation.
Periodontal parameters measured were probing depth (PD), bleeding index (BI), Plaque index (PI), periodontally inflamed surface area (PISA), and clinical attachment level (CAL). Haematological parameters were glycated haemoglobin (HbA1c), fasting blood glucose (FBG), neutrophil-to-lymphocyte ratio (NLR), and white blood cell (WBC) count. For data analysis, poorly controlled T2DM was defined as baseline HbA1c > 7.5%. Statistical significance was defined as p < 0.05. Analysis within and between the two groups was analysed with Student's t-tests when data followed a normal distribution and the Mann-Whitney U test for non-normally distributed data. Chi-square testing was used to compare categorical variables. Uni- and multivariable binary logistic regression was employed to analyze the effectors related to HbA1c decrease. Intention-to-treat analysis was carried out for all enroled participants.
49 participants were enroled in the study; 23 were assigned to the SRP-only group and 26 to the SRP + antibiotics group. Nine participants were lost to follow-up. HbA1c levels decreased significantly after treatment in both the SRP group (7.6 ± 0.98% vs. 7.22 ± 0.88%, p = 0.001) and the SRP + antibiotics group (7.95 ± 1.23% vs 7.42 ± 1.14%, p = 0.004). Following multivariable regression analysis, female sex, adjunctive antibiotic use and high baseline HbA1c levels were associated with a greater decrease in HbA1c levels following periodontal therapy (OR = 9.358, 95%CI: 1.863-47.015; OR = 4.551, 95%CI: 1.012-20.463; OR = 7.162, 95% CI:1.359-37.753). Periodontal parameters significantly improved by a similar amount in both groups after treatment (p < 0.05). When the baseline PD was >6 mm, the SRP+ antibiotic group had more sites of improvement in PD than the SRP only group (698 sites vs 545 sites, p = 0.008).
SRP alone and SRP with adjunctive antibiotics both proved beneficial for improving glycaemic control and periodontal health at 3 months following periodontal therapy. Participants with baseline HbA1c > 7.5% were more likely to show an improvement in HbA1c when receiving adjunctive antibiotics. Adjunctive antibiotic use slightly increased the degree of improvement in probing depths for patients with pocket depths >6 mm and T2DM.
这项单中心短期随机对照试验(RCT)评估了在重度牙周炎合并2型糖尿病(T2DM)患者中,全身应用阿莫西林和甲硝唑作为龈下刮治术(SRP)辅助治疗手段,在3个月期间对血糖控制的影响。作者假设辅助性全身应用抗生素将减少全身炎症,进而改善血糖控制。对所有受试者进行了基线牙周检查和血液学检测。随后,由一名牙周科医生对试验组和对照组进行龈下刮治和根面平整(SRP)操作。试验组在SRP操作的同一周内接受500mg阿莫西林和200mg甲硝唑,每日三次,共7天。三个月后,由盲法检查者重复进行牙周检查,并再次进行血液学检测。此时提供维持性牙周治疗。
采用了2016年至2022年间到牙周科就诊患者的便利样本。纳入的参与者年龄在40 - 75岁之间;诊断为T2DM超过2年;糖化血红蛋白(HbA1c)为6.5 - 10%,有稳定的药物治疗方案且剩余牙齿超过15颗。参与者根据1999年和2018年分类标准,分别被诊断为广泛性重度慢性牙周炎或III - IV期广泛性牙周炎。排除标准包括并存的炎症或感染性疾病(如恶性肿瘤、冠心病或肝炎);饮食或血糖控制策略的调整;严重的糖尿病并发症;妊娠或哺乳期;对阿莫西林或甲硝唑过敏;在过去3个月内接受过牙周治疗或使用过抗生素;吸烟和酗酒。主要临床结局是HbA1c的变化。次要结局包括对牙周参数和炎症血液学标志物的影响。
测量的牙周参数包括探诊深度(PD)、出血指数(BI)、菌斑指数(PI)、牙周炎症表面积(PISA)和临床附着水平(CAL)。血液学参数包括糖化血红蛋白(HbA1c)、空腹血糖(FBG)、中性粒细胞与淋巴细胞比值(NLR)和白细胞(WBC)计数。对于数据分析,控制不佳的T2DM定义为基线HbA1c > 7.5%。统计学显著性定义为p < 0.05。当数据呈正态分布时,两组内和组间分析采用Student's t检验,对于非正态分布数据采用Mann - Whitney U检验。卡方检验用于比较分类变量。采用单变量和多变量二元逻辑回归分析与HbA1c降低相关的影响因素。对所有纳入的参与者进行意向性分析。
49名参与者纳入研究;23名被分配到单纯SRP组,26名被分配到SRP +抗生素组。9名参与者失访。SRP组(7.6 ± 0.98% vs. 7.22 ± 0.88%,p = 0.001)和SRP +抗生素组(7.95 ± 1.23% vs 7.42 ± 1.14%,p = 0.004)治疗后HbA1c水平均显著降低。多变量回归分析后,女性、辅助使用抗生素和高基线HbA1c水平与牙周治疗后HbA1c水平的更大降低相关(比值比 = 9.358,95%置信区间:1.863 - 47.015;比值比 = 4.551,95%置信区间:1.012 - 20.463;比值比 = 7.162,95%置信区间:1.359 - 37.753)。两组治疗后牙周参数均有相似程度的显著改善(p < 0.05)。当基线PD > 6mm时,SRP +抗生素组PD改善的部位比单纯SRP组更多(698个部位对545个部位,p = 0.008)。
单纯SRP以及SRP联合辅助抗生素在牙周治疗后3个月均被证明对改善血糖控制和牙周健康有益。基线HbA1c > 7.5%的参与者在接受辅助抗生素治疗时更有可能出现HbA1c的改善。辅助使用抗生素对袋深>6mm的T2DM患者,探诊深度的改善程度略有增加。